Zoran Rankovic

USPTO Granted Patents = 8 (Patent Applications = 8)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 6.7

ph-index = 1

Location History:

Carmel, IN (US) (2014)
Memphis, TN (US) (2020 - 2023)

Company Filing History:

6 out of 4,442

Eli Lilly and Company

patents

1 out of 260

St. Jude Children's Research Hospital

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12454519 - Substituted N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein (2025-10-28),

2. 12454518 - Substituted N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein (2025-10-28),

3. 11649247 - 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors (2023-05-16),

4. 11629156 - 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors (2023-04-18),

5. 11001596 - 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors (2021-05-11),

6. 10696665 - Mutant IDH1 inhibitors (2020-06-30),

7. 8889856 - Tetrahydropyrrolothiazine compounds (2014-11-18),

8. 8772282 - Tetrahydropyrrolothiazine compounds (2014-07-08),

As a client interested in inventor Zoran Rankovic, I'd like to present an article for your website:

Title: Innovator Spotlight: Zoran Rankovic - Pioneering Cancer Treatments

Introduction:

Zoran Rankovic is a brilliant inventor based in Memphis, TN, with a strong passion for developing groundbreaking pharmaceutical compounds. With a total of 6 patented inventions to his name, Zoran has been at the forefront of innovation in the field of cancer research.

Latest Patents:

Rankovic's latest patents revolve around the development of 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors. These compounds have shown promising results in treating IDH1 or IDH2 mutant cancers, offering new hope for patients battling these challenging diseases.

Career Highlights:

Currently affiliated with Eli Lilly and Company, Zoran Rankovic continues to make significant contributions to the pharmaceutical industry. His work at Eli Lilly has garnered attention for its potential to revolutionize cancer treatment through targeted therapies.

Collaborations:

In his professional journey, Zoran has collaborated with esteemed colleagues such as Renato Alejandro Bauer and Serge Louis Boulet. Together, they have worked tirelessly to advance the development of innovative medicines that could potentially transform the landscape of cancer care.

Conclusion:

In conclusion, Zoran Rankovic stands out as a dedicated inventor whose commitment to scientific excellence is truly commendable. His relentless pursuit of novel solutions for complex medical challenges underscores his significance in the realm of pharmaceutical innovation. As he continues to push the boundaries of cancer research, Zoran's impact on the field is set to be enduring and transformative.

This text is generated by artificial intelligence and may not be accurate.